Healthcare · Biotechnology
Price
$2.09
Market Cap
$19.9M
Employees
23
Beta
1.02
Avg Volume
639,958
CEO
Sabrina Martucci Johnson
Business Description
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-1.74
Stock Price: $2.09
EPS (Diluted): -1.20
EPS (Diluted): -1.20
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
75.90
Stock Price: $2.09
Total Equity: $2.84M
Shares: 111,787,520
Total Equity: $2.84M
Shares: 111,787,520
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.31
Market Cap: $19.90M
Total Debt: $0.00
Cash: $24.71M
EBITDA: -$10.43M
Total Debt: $0.00
Cash: $24.71M
EBITDA: -$10.43M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$193.7M
Market Cap: $19.90M
Total Debt: $0.00
Cash: $24.71M
Total Debt: $0.00
Cash: $24.71M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
209.43
Stock Price: $2.09
Revenue: $1.03M
Shares: 111,787,520
Revenue: $1.03M
Shares: 111,787,520
EV/Sales (Total value vs revenue — works when P/E can't)
API188.02
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
-137.5%
Gross Profit: -$1.42M
Revenue: $1.03M
Revenue: $1.03M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-1,315.5%
Operating Income: -$13.55M
Revenue: $1.03M
Revenue: $1.03M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,300.7%
Net Income: -$13.40M
Revenue: $1.03M
Revenue: $1.03M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
763.4%
Net Income: -$13.40M
Total Equity: $2.84M
Total Equity: $2.84M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-151.4%
Operating Income: -$13.55M
Tax Rate: 0.0%
Equity: $2.84M
Total Debt: $0.00
Cash: $24.71M
Tax Rate: 0.0%
Equity: $2.84M
Total Debt: $0.00
Cash: $24.71M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.14
Current Assets: $27.06M
Current Liabilities: $23.69M
Current Liabilities: $23.69M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $2.84M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $2.84M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.01
Revenue: $1.03M
Shares: 111,787,520
Shares: 111,787,520
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.03
Total Equity: $2.84M
Shares: 111,787,520
Shares: 111,787,520
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.09
Operating CF: -$9.89M
CapEx: -$385,278
Shares: 111,787,520
CapEx: -$385,278
Shares: 111,787,520
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.09
Stock Price: $2.09
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$13.40M
Net Income: -$13.40M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares DARE against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 3:52am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $10.0M | $2.8M | $9,784 | $1.0M |
| Cost of Revenue | $100,000 | $30.1M | $21.6M | $14.3M | $2.4M |
| Gross Profit | $-100,000 | -$20.1M | -$18.8M | -$14.3M | -$1.4M |
| Operating Expenses | $39.0M | $11.2M | $12.1M | $9.2M | $12.1M |
| Operating Income | -$39.1M | -$31.4M | -$30.9M | -$23.5M | -$13.6M |
| Net Income | -$38.7M | -$30.9M | -$30.2M | -$4.1M | -$13.4M |
| EBITDA | -$38.7M | -$30.9M | -$30.7M | -$4.0M | -$10.4M |
| EPS | $-7.52 | $-4.39 | $-4.15 | $-0.48 | $-1.20 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 3:52am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $51.7M | $34.7M | $10.5M | $15.7M | $24.7M |
| Total Current Assets | $55.3M | $43.0M | $17.5M | $18.4M | $27.1M |
| Total Assets | $55.8M | $43.8M | $21.3M | $22.1M | $32.5M |
| Current Liabilities | $16.1M | $31.6M | $20.5M | $21.6M | $23.7M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $17.1M | $32.7M | $26.3M | $28.1M | $29.6M |
| Total Equity | $38.8M | $11.1M | -$5.0M | -$6.0M | $2.8M |
| Retained Earnings | -$110.1M | -$141.1M | -$171.2M | -$175.3M | -$188.7M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 3:52am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$28.8M | -$18.1M | -$38.9M | $5.4M | -$9.9M |
| Capital Expenditure | $-14,524 | $-63,069 | $-629,430 | $-573,046 | $-385,278 |
| Free Cash Flow | -$28.8M | -$18.2M | -$39.5M | $4.8M | -$10.3M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $47.0M | -$17.0M | -$23.9M | $5.2M | $9.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 6:18am (2h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$7.4M $6.2M – $9.1M
|
$34.7M $29.0M – $42.6M
|
$101.9M $85.4M – $125.2M
|
$235.8M $197.6M – $289.6M
|
| EBITDA |
-$4.4M -$5.4M – -$3.7M
|
-$20.8M -$25.5M – -$17.4M
|
-$61.2M -$75.1M – -$51.2M
|
-$141.5M -$173.8M – -$118.5M
|
| Net Income |
-$56.0M -$69.6M – -$42.3M
|
$2.3M $1.8M – $2.9M
|
$157.1M $124.0M – $203.7M
|
$551.7M $435.4M – $715.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 3:52am (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | -71.9% | -99.7% | +10,429.4% |
| Gross Profit Growth | -20,042.2% | +6.5% | +24.1% | +90.1% |
| Operating Income Growth | +19.7% | +1.4% | +24.2% | +42.2% |
| Net Income Growth | +20.0% | +2.5% | +86.6% | -230.6% |
| EBITDA Growth | +20.0% | +0.7% | +86.9% | -159.9% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:19am (2h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-11 | RASTETTER WILLIAM H | A-Award | 10,000.00 | $2.03 | $20,300 |
| 2026-06-11 | Kelley Susan L. | A-Award | 10,000.00 | $2.03 | $20,300 |
| 2026-06-11 | Steele Robin Joan | A-Award | 10,000.00 | $2.03 | $20,300 |
| 2026-06-11 | Matz Gregory W | A-Award | 10,000.00 | $2.03 | $20,300 |
| 2026-06-11 | Grossman Jessica D. | A-Award | 10,000.00 | $2.03 | $20,300 |
| 2026-02-18 | JOHNSON SABRINA MARTUCCI | A-Award | 21,600.00 | $4.00 | $86,400 |
| 2026-02-18 | JOHNSON SABRINA MARTUCCI | A-Award | 10,800.00 | $2.50 | $27,000 |
| 2026-01-30 | JOHNSON SABRINA MARTUCCI | A-Award | 172,000.00 | $1.81 | $311,320 |
| 2026-01-30 | Haring-Layton MarDee | A-Award | 49,000.00 | $1.81 | $88,690 |
| 2025-09-04 | Haring-Layton MarDee | A-Award | 57,000.00 | $2.13 | $121,410 |
| 2025-07-09 | RASTETTER WILLIAM H | A-Award | 4,500.00 | $2.44 | $10,980 |
| 2025-07-09 | Steele Robin Joan | A-Award | 4,500.00 | $2.44 | $10,980 |
| 2025-07-09 | Matz Gregory W | A-Award | 4,500.00 | $2.44 | $10,980 |
| 2025-07-09 | Grossman Jessica D. | A-Award | 4,500.00 | $2.44 | $10,980 |
| 2025-07-09 | Kelley Susan L. | A-Award | 4,500.00 | $2.44 | $10,980 |
| 2025-01-28 | Haring-Layton MarDee | A-Award | 38,000.00 | $3.27 | $124,260 |
| 2025-01-28 | JOHNSON SABRINA MARTUCCI | A-Award | 107,000.00 | $3.27 | $349,890 |
| 2024-06-05 | Grossman Jessica D. | A-Award | 40,000.00 | $0.43 | $17,200 |
| 2024-06-05 | Steele Robin Joan | A-Award | 40,000.00 | $0.43 | $17,200 |
| 2024-06-05 | RASTETTER WILLIAM H | A-Award | 40,000.00 | $0.43 | $17,200 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for DARE — it's generated by the pipeline (
market-narrative step).
No community reviews yet for DARE.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30